Eurofins Scientific SE Share Price
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
09:25:00 15/09/2026 pm IST
|
After hours 01:29:58 am | |||
| 73.48 EUR | +1.83% |
|
73.60 | +0.16% |
| Market Cap | 1.25TCr 1.45TCr 1.18TCr 1.07TCr 2.01TCr 1,38700Cr 2.03TCr 14TCr 5.44TCr 70TCr 5.43TCr 5.31TCr 2,24300Cr | P/E 2026 * |
24.1x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 1.59TCr 1.83TCr 1.5TCr 1.36TCr 2.55TCr 1,76000Cr 2.57TCr 18TCr 6.9TCr 89TCr 6.89TCr 6.74TCr 2,84600Cr | EV / Sales 2026 * |
2.1x | EV / Sales 2027 * | 1.95x |
| Free-Float |
60.39% | Yield 2026 * |
1.11% | Yield 2027 * | 1.26% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
London S.E.
| 0MV5 | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Xetra
| ESF0 | Delayed | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +1.83% | ||
| 1 week | +2.63% | ||
| Current month | +1.30% | ||
| 1 month | +4.32% | ||
| 3 months | +14.67% | ||
| 6 months | +19.52% | ||
| Current year | +17.76% |
| 1 week | 70.2 |  | 73.56 |
| 1 month | 68.38 | | 74.78 |
| Current year | 56.84 | | 74.78 |
| 1 year | 54.86 | | 74.78 |
| 3 years | 39.47 | | 74.78 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/04/26 | Buy | 700 | 0.0004% | |||
| 19/04/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 19/04/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.83% | +2.63% | +15.14% | +33.31% | 1.45TCr | |
| +0.56% | -4.17% | -1.90% | +9.79% | 4.56TCr | |
| -0.01% | -1.18% | +343.46% | +545.09% | 4.4TCr | |
| +1.43% | +4.37% | +45.47% | +27.78% | 4.37TCr | |
| -2.22% | -1.29% | +4.42% | +73.20% | 4.02TCr | |
| -0.73% | -4.72% | +8.55% | +37.89% | 3.19TCr | |
| -9.44% | -11.59% | - | - | 1.74TCr | |
| +4.10% | +5.26% | +25.30% | +122.16% | 1.66TCr | |
| -0.21% | -2.52% | +79.78% | +31.66% | 1.3TCr | |
| +2.12% | +8.48% | +0.77% | -34.37% | 1.3TCr | |
| Average | -0.22% | -1.38% | +57.89% | +94.06% | 2.8TCr | |
| Weighted average by Cap. | -0.19% | -1.88% | +72.90% | +122.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 758.34Cr 875.48Cr 717.09Cr 649.21Cr 1.22TCr 84TCr 1.23TCr 8.56TCr 3.29TCr 43TCr 3.29TCr 3.22TCr 1,35800Cr | 799.78Cr 923.32Cr 756.27Cr 684.68Cr 1.29TCr 89TCr 1.29TCr 9.02TCr 3.47TCr 45TCr 3.47TCr 3.39TCr 1,43200Cr |
| Net income | 53Cr 61Cr 50Cr 45Cr 85Cr 5.88TCr 86Cr 599.1Cr 230.49Cr 2.98TCr 230.23Cr 225.13Cr 9.51TCr | 66Cr 76Cr 62Cr 56Cr 105.99Cr 7.31TCr 106.79Cr 744.42Cr 286.4Cr 3.7TCr 286.08Cr 279.74Cr 12TCr |
| Net Debt | 336.6Cr 388.59Cr 318.29Cr 288.16Cr 540.81Cr 37TCr 544.88Cr 3.8TCr 1.46TCr 19TCr 1.46TCr 1.43TCr 60TCr | 303.37Cr 350.23Cr 286.87Cr 259.71Cr 487.43Cr 34TCr 491.1Cr 3.42TCr 1.32TCr 17TCr 1.32TCr 1.29TCr 54TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | €73.48 | +1.83% | 3,65,667 |
| 14/26/14 | €72.16 | +2.07% | 4,02,823 |
| 11/26/11 | €70.70 | -0.31% | 5,71,619 |
| 10/26/10 | €70.92 | -0.03% | 6,61,722 |
| 09/26/09 | €70.94 | -0.37% | 4,13,214 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
